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The large number of cell divisions required to make a
human body inevitably leads to the accumulation of
somatic mutations. Such mutations cause individuals to
be somatic mosaics. Recent advances in genomic tech-
nology now allowmeasurement of somatic diversity. Initial
studies confirmed the expected high levels of somatic
mutations within individuals. Going forward, the big ques-
tions concern the degree to which those somatic muta-
tions influence disease. Theory predicts that the frequency
of mutant cells should vary greatly between individuals.
Such somatic mutational variability between individuals
could explain much of the diversity in the risk of disease.
But how variable is mosaicism between individuals in
reality? What is the relation between the fraction of cells
carrying a predisposing mutation and the risk of disease?
What kinds of heritable somatic change lead to disease
besides classical DNA mutations? What molecular pro-
cesses connect a predisposing somatic change to dis-
ease? We know that predisposing somatic mutations
strongly influence the onset of cancer. Likewise, neurode-
generative diseases may often begin from somatically
mutated cells. If so, both neurodegeneration and cancer
may be diseases of later life for which much of the risk
may be set by early life somatic mutations.
Introduction
For many years, human bodies were typically thought of as
genetically uniform. Rare cellular mutations in cancer or
other diseases were known but generally considered to be
aberrations. As technology and genetic understanding
slowly improved, the idea began to spread that individuals
may often be genetic mosaics. Scattered observations,
particularly of skin diseases (Figure 1), suggested that there
may be much hidden variability within bodies. But the actual
amount of mosaicism and its consequences remained un-
clear. Most investigators paid little attention to the subject.
Theory suggested that human bodies should, in fact, be
mosaics of genetic mutations [1]. A body has about N =
1014 cells, each of which arose from a cell division. If the so-
maticmutation rate for each gene per cell division is u = 1026,
then each gene suffers approximately Nu = 108 somatic
mutational events. The number of mutated cells may be
higher, because a single mutational event early in develop-
ment will be carried forward to all descendant cells. Although
the initial theory predicted significant genetic mosaicism, it
had little impact. It was hard to measure the actual level of
mosaicism, and there was little evidence that widespread
mosaicism might have important consequences.
Later theories then suggested, even more strongly, that
somatic mosaicism could be widespread and be a very
strong factor in determining the variability in disease risk
between individuals [2–5]. In particular, some individuals
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will have their first mutation later in development and have
fewer somatically mutated cells. The inevitable variation in
the degree of somatic mosaicism arising early in life could
determine much of the variation in the risk of disease later
in life [2–5]. If so, that would explain a lot about the unknown
causes of disease. How can we know if it is true?
Only recently, it has become possible to analyze the
genomes of single cells or small samples of cells. This has
opened a new window onto the actual mutational diversity
within individuals, and several recent studies demonstrate
widespread somatic mosaicism [1,6–16]. However, the exis-
tence of somatic diversity tells us relatively little about
disease. In this review, I consider what steps are needed to
connect somatic diversity to disease progression and to
the variation in disease risk between individuals.
What types of disease may be affected by somatic mosa-
icism? Certainly mosaicism may influence cancer, in which
somatic mutations play a central role [17]. However, in the
typical view of cancer, isolated somatic mutations occur in
rare cells, and disease develops only when those isolated
cells acquire multiple mutations. By contrast, a perspec-
tive of common and highly variable somatic mosaicism
emphasizes that some individuals will inevitably have many
mutated cells that strongly predispose to disease by
increasing the number of cells that carry an initial predispos-
ing somatic mutation [3]. The recent theory and observations
onmosaicism are just starting to change the common view of
the events that initiate cancer from rare isolated somatic
mutations to the potentially important role of widespread
somatic mosaicism.
It is also possible that somatic mosaicism influences
neurodegenerative disease [1,4,6–9,12–16,18]. However,
the importance of somatic mutation in neurodegeneration
remains unclear. In cancer, a tumor is thought to arise from
a somatically mutated cell that initiates a clonal expansion.
In neurodegeneration, how would a small focus of somati-
cally mutated cells initiate the spread of disease? Several
possibilities have been discussed, but the problem remains
open [4,8,18–21]. If neurodegeneration does tend to spread
from a small initial focus of damaged cells, then somatic
mosaicismmay be a primary risk factor in neurodegenerative
disease.
Direct Evidence of Mosaicism
Numerous recent genomic studies describe widespread
somatic mosaicism [12,13], following early hints from
patterns of skin disease (Figure 1). Those recent genomic
studies provide the proof of existence for what seemed
theoretically inevitable, setting the stage for future progress.
In a study of primary fibroblast cells obtained from seven
different humans, Abyzov et al. [14] estimate ‘‘that approxi-
mately 30% of the fibroblast cells have CNVs (copy number
variants) in their genomes.’’ CNVs correspond to deletions
or duplications of genomic regions that are at least a few
kilobases (kb) in length. A rough theory predicts that the
average frequency of cells with a somatic mutation should
be approximately the number of cellular generations since
the zygote stage multiplied by the mutation rate per cell divi-
sion [2–4,22]. For 30 generations from an adult fibroblast
back to the zygote, a 30% frequency of mutated cells is
Figure 1. Examples of somatic mosaicism
in skin.
These patterns illustrate the spatial distribu-
tion of altered cells associated with cellular
changes that transmit to descendant cells.
These extreme cases hint at the more
frequent cases of mosaicism that go unde-
tected because they occur in fewer cells or
do not produce easily observed phenotypes
known to arise from a mosaic cause. Several
mosaic skin diseases are associated with
known mutations. Other skin patterning may
be caused by various epigenetic changes
that transmit to daughter cells. All figures are
presented and discussed in Happle [32].
(A) Brindle trait of dogs (reproduced from
Harlis.jpg, Creative Commons). (B) Classic
patterning of human skin mosaicism in which
affected cells follow the lines of Blaschko. (C)
Zimmermann-Laband syndrome showing
typical pattern of pigment lines on the skin.
(D) Systematized sebaceous nevus, which
has been associated in some cases with
somatic HRAS or KRAS mutations [33,34]
(with kind permission from Springer Science
and Business Media, from [29]). (E) Type 2
segmental PTEN hamartoma syndrome,
apparently caused by a germline mutation
that leads to heterozygosity at the PTEN
locus, followed by somatic mutations that
cause mosaic loss of heterozygosity in some
cells [35,36] (reprinted with permission from
John Wiley & Sons [36]). (F) Type 1 segmental
Darier disease, associated with de novo so-
matic mutations in some cases [37,38] (with
kind permission from Springer Science and
Business Media, from [29]).
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division. That rate seems reasonable or perhaps a bit conser-
vative for the genome-wide CNV changes per cellular gener-
ation [23]. In another study, McConnell et al. [15] estimated
that 13–41% of human frontal cortex neurons have at least
one somatic CNV of a megabase or more, and O’Huallachain
et al. [16] found widespread somatic CNVs in diverse human
tissues.
These genome-wide studies of CNVs emphasize high fre-
quency mutational events that lead to a high frequency of
somatically mutated cells. When focusing on a single gene
or on a class of mutations with lower frequency, we face
the empirical difficulty that only a small fraction of cells are
typically expected to carry a somatic mutation, even though
the total number of mutant cells may be large. Using the
theory mentioned above, the frequency of mutated cells
would on average be approximately uG, where u is the muta-
tion rate per cellular generation, and G is the number of
cellular generations since the zygote stage. If we focus on
a single gene with a mutation rate of 1026 [24], and we as-
sume that G is roughly 30, then the frequency of mutated
cells is on the order of 1025. However, in a large cellular pop-
ulation that greatly exceeds 105, very many cells carry a so-
matic mutation. So we arrive at one of the essential empirical
difficulties. It is often hard to detect low frequencymutations,
but mutations in low frequency may be carried by very
many cells and may be significant with regard to disease
processes.
Two studies are interesting in light of this distinction
between frequency and number [10,11]. These studiesanalyzed large chromosomal abnormalities of the sort often
associated with leukemia. In cancer-free individuals under
50 years, the frequency of individuals with somatic mosai-
cism was estimated to be 0.23% [11] or under 0.5% [10].
The frequency of mosaic individuals rose with age, reaching
2–3% in the elderly. Among all cancer-free individuals,
mosaicism increased the risk of subsequent progression to
leukemia. Those studies could detect only large chromo-
somal abnormalities in individuals with at least 5% of cells
carrying the abnormality. The vast majority of mosaicism is
expected to occur at a frequency of less than 5%. Thus,
many of the mosaic individuals may have had a clonal
expansion of the mutant before detection.
Interpreting these studies in terms of variable mosaicism
would require information about the origin of the first muta-
tion. On the one hand, the mutation may have occurred dur-
ing development, causing the mutant to be carried in early
life by many descendant hematopoietic stem cells, although
often in low or moderate overall frequency but typically
below the 5% level required for detection. Subsequentmuta-
tions within this population of developmentally mutated cells
may have led to a clonal expansion and a rise in frequency
above the 5% detection level. In this case, the develop-
mental mutation and early life mosaicism would have been
the main factor in setting the risk of subsequent clonal
expansion that led to a detectable level of mosaicism. On
the other hand, the first chromosomal mutation may have
happened after development, and the subsequentmutations
that caused a clonal expansion must have occurred among
the very rare mutated cells.
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dividuals.
Each figure shows a phylogenetic tree repre-
sentation of the cellular lineage history within
an individual, rooted at the zygote. The
history represents only a particular, very small
genomic region. The lighter-colored lines
specify mutant cells and their descendants.
(A) This individual had an early somatic muta-
tion, which caused a high frequency of adult
cells to carry the mutation, shown by the large
colored area in the body. A second, later
mutation carried forward to a smaller set of
adult cells, and a third mutation happened in
the last division before the current adult cell.
The different stages of development at which
the mutants arose cause a mixture of wide-
spread and restrictedmutant cell populations.
(B) A different individual had only a single
somatic mutation relatively late in develop-
ment, causing limited mosaicism. The actual
amount of mosaicism for a small genomic
region must be vastly greater than illustrated.
For N cell divisions and a mutation rate of u
per cell division, Nu mutational events occur
in the somatic history of an individual. For
approximately 1016 cell divisions in a typical
human lifetime and a mutation rate of roughly
1026 for a small gene-sized genomic region,
that region will experience on the order of
1010 mutational events over the lifetime of an
individual. Most of those mutations will be in
the last cell division, but some will occur early
in development, causing widespread mosai-
cism and variability between individuals.
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invokes an initial mutation in relatively few stem cells. By
contrast, the widespread mosaicism caused by develop-
mental mutations is a more recently developed idea that
has been increasingly invoked to explain the origin of dis-
ease [1,2,25–27]. Given the complexity of these two alterna-
tive scenarios, howcanwe assess the fraction of disease risk
caused by developmental mutations and early life
mosaicism?
Variability in the Risk of Disease
It will not be easy to connect variation in disease risk to
developmental mutations that cause variation in early life
mosaicism. But it is a topic worth pursuing, because much
of the unexplained cause of disease in later life may trace
back to early developmental mutations.
The following questions set the agenda: How variable is
mosaicism between individuals? If mosaicism is common
but at approximately the same level in each individual, then
mosaicism cannot explain why some individuals get sick
and others do not. However, theory suggests very high
variability in mosaicism [2–5]. In essence, there should be a
continuum between individuals for the frequency of adult
cells that carry a particular mutation. Rare individuals carry
the mutation in all cells by germline inheritance or by
de novo somatic mutation in the zygote. More individuals
carry a lower frequency of an inherited somatic mutation
because, as the zygote divides, more cells become a target
for a de novo somatic mutation, increasing the frequency
of individuals in the population who suffer such mutations
while simultaneously decreasing the associated fraction of
mutated adult cells (Figure 2).What is the relation between the fraction of cells carrying a
predisposing mutation and the risk of disease? In cancer,
certain germline mutations shift disease onset to earlier
ages [3,17,28,29]. Often, somatic mutations of the same
genes initiate the same disease, but typically cause a later
age of onset. The difference in the age of onset between
germline and somatic mutations matches closely the ex-
pected difference in the frequency of adult cells that are
expected to carry the mutation [30]. However, the available
data only allow a comparison between individuals who carry
a germline mutation that is present in all adult cells and all
other individuals who have a particular average frequency
of cells carrying a somatic mutation. In contrast, theory sug-
gests wide variability between individuals in the frequency of
somatically mutated cells and thus a continuum of risk
between individuals [2–5]. Germline mutations or initial
somatic mutations in the zygote are carried forward to all
adult cells and should be associated with the earliest age
of onset. Increasingly later mutations in development are in
a decreasing fraction of an individual’s cells, which should
associate with a continuous shift to later ages of disease
onset.
The big questions arewhether an increase in the fraction of
somatically mutated cells shifts disease to an earlier age,
and what fraction of disease is caused by early develop-
mental mutations. It seems almost certain that, for cancer,
the frequency of cells that carry a somatic mutation will
strongly influence the age of onset. But the strength of the
association will likely vary between tissues. For example, in
tissues that divide relatively rarely later in life, mosaicism
caused by early-life mutations may dominate risk. By
contrast, in renewing epithelial tissues that divide frequently
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ating mutations to occur later in life and thus a lower fraction
of the total late-life disease risk may be set by early-life
mutations.
For neurodegeneration or other diseases, the association
between the frequency of somatically mutated cells and
disease remains unknown. Neurodegeneration is a hetero-
geneous collection of diseases, so onemust be careful about
generalizing from one example to the broader problem. At
present, some analogies exist between how the ages of
onset for cancer and neurodegeneration may respond to
inherited versus somatically acquired mutations [4,6–9,18].
In one extreme example, an early somatic mutation in
the human prion protein gene occurred in nearly all adult
cells [6]. That individual suffered the same early-life onset
(age 46) and symptoms of Creutzfeldt-Jakob disease that
are often found in people who inherit a germline mutation
in the same gene. The disease similarity between cases
with either a germline or somatic mutation in nearly all cells
is not surprising. The interesting problem concerns the
change in risk profile for individuals who carry a somatic mu-
tation in a decreasing fraction of somatic cells.
To understand how risk changes with the frequency of
mutant cells, we must understand which molecular pro-
cesses connect a predisposing mutation to disease? For
cancer, there is enough evidence to understand how molec-
ular processes may connect the frequency of mutated cells
to tumor initiation [3,17]. By contrast, it is not clear at present
whether an associationmight exist between the frequency of
mutated cells and neurodegeneration and, if so, what sort of
molecular processes would cause that association. Many
possibilities have been raised [4,6–9,18–21]. Misfolded pro-
teins may spread by prion-like processes. The initial seeds
for misfolding may first arise in a small focus of somatically
mutated cells. Alternatively, changed RNAs may first arise
in a few mutated cells, and then move extracellularly to alter
other cells [31]. In principle, any factor that can transform a
naı¨ve cell into a producer of that same factor may potentially
spread in an infectious way. If a mutated cell is at higher risk
for becoming transformed to seed initiation of the infectious
process, then there will be an association between the frac-
tion of mutated cells and the risk of disease. In addition, a
higher fraction of mutated cells will be associated with an
earlier age of onset.
How does the lineage history of cells during development
affect the relation between mutational events and muta-
tional frequency in different tissues? In the simplest model,
a whole tissue would derive from a single ancestral cell, and
descendants from that ancestral cell would not contribute to
other tissues. Such partitioning would lead to a smooth
continuum between the number of cellular generations
that a mutation occurred after the tissue-specific progenitor
and the frequency of mutant cells in that tissue. However,
tissues inevitably derive from mixing between cellular line-
ages. More mixing may reduce the variance between
individuals in the frequency of mutated cells. Advancing
genomic technology combined with the computational
methods of lineage (phylogenetic) reconstruction will even-
tually provide a sense of the developmental map and the
degree of lineage mixing in different tissues. Studies on
whole cadavers with cell-level genomic resolution will be
particularly valuable for learning about cellular lineage
histories within individuals and somatic mutational diversity
between individuals.What kinds of heritable somatic change lead to disease
besides classical DNA mutations? I have emphasized muta-
tions to the primary DNA sequence. However, any somatic
cellular change that transmits heritably to descendant cells
will have consequences similar to a change in the DNA,
including various non-genetic (epigenetic) changes. The
key processes concern the rate at which changes arise in
cells and the rate at which such changesmay decay or revert
back to the original state in descendants. I focused on DNA
mutations because they provide a simple way to compare
germline and somatic changes, and because most data are
about DNA changes. As the technology to measure other
types of change improves, we will obtain better estimates
for the relative importance of different kinds of heritable
somatic change in relation to disease.Conclusion
In summary, a human body contains about 1014 cells and
produces about 1016 cells over the course of a lifetime.
That huge population size probably exceeds the total
number of primates that have ever existed. The scope for
diversity within bodies is great. Until recently, technology
limited our ability to see into individuals andmeasure cellular
diversity. New genomic methods have opened a window
onto that diversity. We are now poised to understand how
somatic diversity affects the risk of disease. Themost impor-
tant problem concerns how much the inevitable variability
between individuals translates into differences in disease.
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